Prelude Therapeutics - PRLD Stock Forecast, Price & News

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Prelude Therapeutics Stock Performance

PRLD Stock opened at $6.17 on Monday. The company has a market capitalization of $294.28 million, a P/E ratio of -2.39 and a beta of 0.75. Prelude Therapeutics has a 52-week low of $3.87 and a 52-week high of $43.55. The business has a 50-day simple moving average of $5.16 and a two-hundred day simple moving average of $6.56.

Prelude Therapeutics (NASDAQ:PRLD - Get Rating) last announced its earnings results on Tuesday, May 10th. The company reported ($0.63) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.05. As a group, sell-side analysts forecast that Prelude Therapeutics will post -2.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on PRLD shares. HC Wainwright reduced their target price on Prelude Therapeutics from $62.00 to $16.00 and set a "buy" rating for the company in a research note on Thursday, May 12th. Jefferies Financial Group started coverage on Prelude Therapeutics in a research note on Friday, July 29th. They issued a "buy" rating and a $9.00 target price for the company. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Prelude Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $13.20.

Insider Transactions at Prelude Therapeutics

In other Prelude Therapeutics news, CFO Laurent Chardonnet bought 10,000 shares of the business's stock in a transaction dated Wednesday, June 1st. The shares were purchased at an average price of $4.23 per share, for a total transaction of $42,300.00. Following the purchase, the chief financial officer now directly owns 24,500 shares of the company's stock, valued at $103,635. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 77.38% of the company's stock.